TP53 and diffuse large B-cell lymphoma: TP53 mutation is a critical adverse genetic alteration in DLBCL (35), associated with resistance to multiple therapeutic modalities, including conventional immunochemotherapy (36), autologous stem-cell transplantation (37), and CAR-T therapy (21).